Arthur Hewig Amgen Inc.

Art Hewig is an Executive Director of Process Development at Amgen where he leads an integrated group that is designed to deliver early phase end-to-end drug substance processes. His team bridges the R&D and Manufacturing organizations and serves them by enabling fast to clinic approaches as well as developing state-of-the-art processes to manufacture molecules in Amgen’s synthetics and biologics pipeline. This team incorporates and develops the best technical advances and combines them with extensive commercial process development experience to develop robust processes. This includes developing manufacturing platforms for new modalities entering Amgen’s early phase pipeline. Art has been with Amgen since 2002 and has held numerous scientific and leadership roles for both early and late phase Process Development. Art holds a PhD in Chemical Engineering from Carnegie Mellon University.